SoftOx Solutions is trading 13.34% up now at NOK 0.10, with the move best characterized as sector-led amid stronger biotech sentiment; direct causation is unconfirmed.
- The latest public development remains August 11 first-patient dosing in the SIS-03 proof-of-concept trial.
- No new company-specific announcement was identified for August 25–26, 2026.